StockData

Palisade Bio vs Yarrow Bioscience

PALI and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PALI and YARW compare

Palisade Bio is the larger company, worth 4.6 times as much as Yarrow Bioscience ($176M against $37.9M).

Yarrow Bioscience keeps more of each dollar of sales as profit, with a net margin of −4646% compared with −6388% at Palisade Bio.

Yarrow Bioscience pays a dividend yielding 142%; Palisade Bio does not pay one.

Yarrow Bioscience scores higher on the StockData Score (11 against 7 for Palisade Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPALIYARW
Size and price
Market cap$176M$37.9M
Share price$1.01$14.21
Change, 1 year−52.8%−24.1%
Change, 5 years−99.9%−98.5%
Beta (5Y)1.152.07
Employees100K10
StockData Score
Total score711 (better)
Valuation score11
Growth score01 (better)
Performance score11
Health score55
Dividend score03 (better)
Valuation
P/S352×66.6× (better)
P/B1.4× (better)1.7×
FCF yield–−87.3%
Fair value–$7.04
Margin of safety–−102%
Growth
Revenue growth (TTM)–13.8%
Revenue growth, 5Y average–−51.4%
Profitability
Operating margin−7070%−5219% (better)
Net margin−6388%−4646% (better)
FCF margin–−5811%
Return on equity−51.4% (better)−86.9%
Financial health
Debt / equity0.000.00
Interest coverage−4418.6×–
Current ratio24.26 (better)15.26
Altman Z-score19.21 (better)−33.58
Piotroski F-score4 (better)3
Dividends and buybacks
Dividend yield–142%
Buyback yield−74.7%–
Shareholder yield−74.7%142% (better)
Ownership
Held by institutions99.5%11.6%
Held by insiders4.7%82.1%
Insider net buying, 12 months−$124K–
Short interest, % of float17.6%29.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.